



Nonprofit corporations and independent licensees
of the Blue Cross and Blue Shield Association

Medical benefit drug policies are a source for BCBSM and BCN medical policy information only. These documents are not to be used to determine benefits or reimbursement. Please reference the appropriate certificate or contract for benefit information. This policy may be updated and therefore subject to change.

P&T Date: 06/11/2026

Hemgenix[®] (etranacogene dezaparvovec-drlb)

HCPCS: J1411

Policy:

Requests must be supported by submission of chart notes and patient specific documentation.

- A. Coverage of the requested drug is provided when all the following are met:
 - a. FDA approved age
 - b. Diagnosis of moderate to severe hemophilia B
 - c. Prescribed by or in consultation with a hematologist providing attestation of knowledge the patient is suitable for treatment, including the AAV5 viral vector antibody titer
 - d. Must currently be on factor IX therapy with greater than 150 prior exposure days to treatment
 - e. Must not have a history of inhibitors to factor IX or a positive inhibitor screen defined as greater than or equal to 0.3 Bethesda units prior to administration of Hemgenix
 - f. Must not have received prior treatment with any gene therapy for hemophilia B or are being considered for treatment with any other gene therapy for hemophilia B
 - g. Must be being treated at a federally recognized hemophilia treatment center site
 - h. The requesting physician attests to providing clinical outcome information within the appropriate provider portal as requested by BCBSM
 - i. Trial and failure, contraindication, OR intolerance to the preferred drugs as listed in BCBSM/BCN's utilization management medical drug list
- B. Quantity Limitations, Authorization Period and Renewal Criteria
 - a. Quantity Limits: Align with FDA recommended dosing
 - b. Authorization Period: 3 months
 - c. Renewal Criteria: Not applicable as no further authorization will be provided

***Note: Coverage and approval duration may differ for Medicare Part B members based on any applicable criteria outlined in Local Coverage Determinations (LCD) or National Coverage Determinations (NCD) as determined by Center for Medicare and Medicaid Services (CMS). See the CMS website at <http://www.cms.hhs.gov/>. Determination of coverage of Part B drugs is based on medically accepted indications which have supported citations included or approved for inclusion determined by CMS approved compendia.

Background Information:

- Hemgenix is an adeno-associated virus vector-based gene therapy indicated for the treatment of adults with hemophilia B who currently use factor IX prophylaxis therapy, or have a current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes.
- Hemophilia B is a rare genetic bleeding disorder in which affected individuals have insufficient levels of factor IX. It is the second most common type of hemophilia and caused by mutations in the F9 gene. The F9 gene is located on the X chromosome and thus the disease is inherited as an X-linked recessive trait. About 30% of cases are the result of spontaneous genetic mutations. Studies report that over 50% of people newly diagnosed with severe hemophilia have no prior family history. Overall incidence is estimated at 1 in 25,000 male births.
- The symptoms and severity of hemophilia B may vary greatly from one person to another. Hemophilia B can range from mild to moderate to severe.
 - Mild hemophilia patients have a factor activity of 5% to 40% and usually do not experience any major problems in everyday life. It often goes unnoticed until puberty or adulthood when bleeding after surgery or a deep cut lasts longer than normal. These patients do not typically need prophylactic therapy and only require on-demand factor for injuries or surgeries.
 - Moderate hemophilia patients have a factor activity of 1% to 5% and may have occasional episodes of spontaneous bleeding from deep tissues such as joints and muscles. These episodes are usually associated with some injury or inciting event. Individuals with moderate hemophilia B are at risk for prolonged bleeding following surgery or trauma. Affected individuals are usually diagnosed by 5 or 6 years of age. The frequency of spontaneous bleeding episodes in individuals with moderate hemophilia B is highly variable resulting in some patients needing consistent prophylactic factor IX and others only needing on-demand factor IX for medical procedures.
 - Severe hemophilia patients have a factor level of less than 1% and often have bleeding for no known reason, especially in the joints and muscles. From infancy, patients bruise easily and as they become more active, learn to walk, and put more strain on their joints and muscles, bleeding starts to occur. Without preventative treatment, a young child may experience 2 to 5 spontaneous bleeding episodes per month.
- Hemophilia B should be suspected in individuals presenting with a history of easy bruising, spontaneous bleeding, particularly into the joints, muscles, and soft tissues, or excessive bleeding following trauma or surgery. If hemophilia is suspected, the clinician should obtain the patient's bleeding history and family history of abnormal or unexplained bleeding experienced by any siblings or maternal male relatives to assess patterns of inheritance and assist with diagnosis. A definitive hemophilia B diagnosis is based on a factor assay to demonstrate a deficiency of factor IX. Once an individual is diagnosed with hemophilia B, the specific mutation in the F9 gene responsible for causing hemophilia may be identified.
- The current standard of care for hemophilia B is the use of factor IX replacement therapy. There are two types of factor products available to treat hemophilia which include plasma derived factor, entirely made of plasma from human donations and recombinant factor, which is made by genetically engineered technology, both with standard and extended half-life products. All factor products have demonstrated to have similar safety and efficacy in clinical studies treating or reducing bleeding episodes with the apparent difference in the frequency of administration: up to three times weekly injections for standard products and weekly or every two weeks for extended half-life products. To be enrolled in the HOPE-B trial, patients needed to be stable on factor IX therapy for 6 months prior Hemgenix administration.

- It is estimated that less than 5% of individuals with severe hemophilia B develop inhibitors against factor IX replacement therapy. Inhibitors most often develop during childhood, especially during the first 20 exposure days. Exposure days are counted as a day during which a patient receives factor. Controlling bleeds is a greater challenge in hemophilia patients with inhibitors than in those without. Inhibitors to factor IX are associated with a higher disease burden, including increased risk of musculoskeletal complications, pain, physical limitations, and treatment challenges, all of which may impact a patient's physical functioning, capacity for physical activities, and quality of life. The definition of a positive inhibitor is a Bethesda titer of greater than or equal to 0.3 BU for factor IX. Patients positive for factor IX inhibitors or with a prior history of factor IX inhibitors were excluded from the HOPE-B trial. In order to limit the risk of inhibitor development following Hemgenix therapy, the HOPE-B study also required patients had greater than 150 prior exposure days to factor IX therapy before receiving gene therapy.
- Hemgenix uses an adeno-associated virus serotype 5 vector (AAV5) to deliver a functional copy of the F9 gene to the patient's liver where functional factor IX is produced. Patients with high AAV5 antibody titers may not respond to gene therapy due to the antibodies neutralizing Hemgenix before the functional F9 gene can be properly incorporated into the patient's genome. The HOPE-B study did not exclude patients from the trial based on antibody titers, however, the trial had one non-responder to treatment whose antibody titer level was 1:700. It is important for physicians to be aware of the patients antibody titer levels before administering treatment.
- A provider portal is used to capture clinical outcome information for patients on select high-cost treatments, such as gene and cellular therapies. If a patient meets medical necessity as defined by this policy and is approved for treatment, the requesting physician must attest to providing clinical outcome information within the appropriate provider portal at the requested cadence.

References:

1. Hemgenix [prescribing information]. King of Prussia, PA: CSL Behring LLC; January 2025.
2. Clinicaltrials.gov. HOPE-B: Trial of AMT-061 in severe or moderately severe hemophilia b patients (NCT03569891). Available at: <https://clinicaltrials.gov/ct2/show/NCT03569891>. Accessed on November 22, 2022.
3. Shapiro AD. Hemophilia b. 2018. Available at: <https://rarediseases.org/rare-diseases/hemophilia-b/>. Accessed on November 22, 2022.
4. World Federation of Hemophilia. Guidelines for the management of hemophilia. Haemophilia. 2020 August 3. Available at: <https://onlinelibrary.wiley.com/doi/epdf/10.1111/hae.14046>. Accessed on: November 22, 2022.
5. Carcao M and Goudemand J. Inhibitors in hemophilia: a primer. 2018 Nov. Available at: <https://www1.wfh.org/publication/files/pdf-1122.pdf>. Accessed on November 22, 2022.
6. World Federation of Hemophilia. The WFH guidelines for the management of haemophilia: AAV gene therapy. Haemophilia. 2025 Jan/Feb; 32 (1): 20 – 54.

Policy History												
#	Date	Change Description										
1.7	Effective Date: 06/11/2026	Annual review of criteria was performed, no changes were made										
1.6	Effective Date: 06/05/2025	Updated to change the provider portal from Audaire Health to the appropriate provider portal										
1.5	Effective Date: 06/06/2024	Annual review of criteria was performed, no changes were made										
1.4	Effective Date: 06/08/2023	Removed confirmation of diagnosis via decreased factor IX levels										
1.3	Effective Date: 02/02/2023	New policy										
1.2	Effective Date: 12/08/2022	UM medical management system update for BCBS and BCN <table><tr><th>Line of Business</th><th>PA Required in Medical Management System (Yes/No)</th></tr><tr><td>BCBS</td><td>Yes</td></tr><tr><td>BCN</td><td>Yes</td></tr><tr><td>MAPPO</td><td>Yes</td></tr><tr><td>BCNA</td><td>Yes</td></tr></table>	Line of Business	PA Required in Medical Management System (Yes/No)	BCBS	Yes	BCN	Yes	MAPPO	Yes	BCNA	Yes
Line of Business	PA Required in Medical Management System (Yes/No)											
BCBS	Yes											
BCN	Yes											
MAPPO	Yes											
BCNA	Yes											
1.1	Effective Date: 12/02/2022	UM medical management system update for MAPPO and BCNA <table><tr><th>Line of Business</th><th>PA Required in Medical Management System (Yes/No)</th></tr><tr><td>BCBS</td><td>No</td></tr><tr><td>BCN</td><td>No</td></tr><tr><td>MAPPO</td><td>Yes</td></tr><tr><td>BCNA</td><td>Yes</td></tr></table>	Line of Business	PA Required in Medical Management System (Yes/No)	BCBS	No	BCN	No	MAPPO	Yes	BCNA	Yes
Line of Business	PA Required in Medical Management System (Yes/No)											
BCBS	No											
BCN	No											
MAPPO	Yes											
BCNA	Yes											
1.0	Effective Date: 10/06/2022	Preliminary drug review										

* The prescribing information for a drug is subject to change. To ensure you are reading the most current information it is advised that you reference the most updated prescribing information by visiting the drug or manufacturer website or <http://dailymed.nlm.nih.gov/dailymed/index.cfm>.

Blue Cross Blue Shield/Blue Care Network of Michigan
Medication Authorization Request Form
Hemgenix® (etranacogene dezaparvovec-drlb)
HCPSC CODE: J1411



Nonprofit corporations and independent licensees
of the Blue Cross and Blue Shield Association

This form is to be used by participating physicians to obtain coverage for Hemgenix. For commercial members only, please complete this form and submit via fax to 1-877-325-5979. If you have any questions regarding this process, please contact BCBSM Provider Relations and Servicing or the Medical Drug Helpdesk at 1-800-437-3803 for assistance.

PATIENT INFORMATION	PHYSICIAN INFORMATION
Name	Name
ID Number	Specialty
D.O.B. ☐ Male ☐ Female	Address
Diagnosis	City /State/Zip
Drug Name ☐ Hemgenix	Phone/Fax: P: () - F: () -
Dose and Quantity	NPI
Directions	Contact Person
Date of Service(s)	Contact Person Phone / Ext.

STEP 1: DISEASE STATE INFORMATION

- Is this for initiation or continuation of therapy?
☐ Initiation ☐ Continuation *Date patient started therapy:* _____
- Please provide the NPI number for the place of administration: _____
- Please specify the location of administration (e.g. name of facility):

- Is this medication prescribed by or in consultation with a hematologist? ☐ Yes ☐ No *Comment:* _____
- Initiation AND Continuation of therapy:**
 - What is the patient's diagnosis?
☐ Hemophilia B (congenital Factor IX deficiency) confirmed via factor IX assay showing decreased factor IX levels
☐ Other – *please specify diagnosis:* _____
 - Has the patient had their adeno-associated virus stereotypic 5 vector (AAV5) antibody titer tested?
☐ Yes ☐ No *Comment:* _____
 - Does the patient have severe disease defined as a factor IX levels less than 5% of normal?
☐ Yes, Please specify IX level: _____ ☐ No ☐ Unknown
 - Is the patient currently on factor IX therapy with greater than 150 prior exposure days to treatment?
☐ Yes, Please specify number of exposure days to treatment: _____ ☐ No ☐ Unknown
 - Does the patient have a history of inhibitors to factor IX?
☐ Yes, Please specify: _____ ☐ No ☐ Unknown
 - Does the patient have a history of a positive inhibitor screen defined as greater than or equal to 0.3 Bethesda units prior to administration of Hemgenix?
☐ Yes, Please specify: _____ ☐ No ☐ Unknown
 - Has the patient received prior treatment with any gene therapy for hemophilia B or is being considered for treatment with any other gene therapy for hemophilia B? ☐ Yes ☐ No *Comment:* _____
- Continuation of therapy** - *Please include rationale for continuation of therapy* _____
- Please add any other supporting medical information necessary for our review

Coverage will not be provided if the prescribing physician's signature and date are not reflected on this document.

☐ Request for expedited review: I certify that applying the standard review time frame may seriously jeopardize the life or health of the member or the member's ability to regain maximum function

Physician's Name	Physician Signature	Date
Step 2: Checklist	☐ Form Completely Filled Out ☐ Attached necessary chart notes	☐ Important laboratory results
Step 3: Submit	By Fax: BCBSM Specialty Pharmacy Mailbox 1-877-325-5979	By Mail: BCBSM Specialty Pharmacy Program P.O. Box 312320, Detroit, MI 48231-2320

Confidentiality notice: This transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reliance on the contents of this document is strictly prohibited. If you have received this in error, please notify the sender to arrange for the return of this document.